Filing Details

Accession Number:
0001127602-10-006066
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-02-24 12:00:00
Reporting Period:
2010-02-22
Filing Date:
2010-02-24
Accepted Time:
2010-02-24 15:35:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1199306 Anna Richo One Amgen Center Drive
Thousand Oaks CA 91320-1799
Svp & Cco No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-02-22 100 $57.00 3,006 No 4 S Indirect The Nicholas A. Moore and Anna S. Richo Family Trust
Common Stock Disposition 2010-02-22 350 $57.00 2,656 No 4 S Indirect The Nicholas A. Moore and Anna S. Richo Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect The Nicholas A. Moore and Anna S. Richo Family Trust
No 4 S Indirect The Nicholas A. Moore and Anna S. Richo Family Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 13,229 Direct
Common Stock 1,936 Indirect 401(k) Plan
Footnotes
  1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 5,000 RSUs which vests in two equal annual installments of 2,500 each commencing 7/31/2010; 2,529 RSUs which vest in three equal annual installments of 843 each commencing 4/29/2010; and 5,700 RSUs which vests in four equal annual installments of 1,425 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person.
  2. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.